Michael Cherny
Stock Analyst at B of A Securities
(4.11)
# 342
Out of 5,182 analysts
121
Total ratings
56.38%
Success rate
11.63%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Buy | $1,040 → $1,000 | $822.63 | +21.56% | 16 | Apr 6, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $18 → $25 | $26.33 | -5.05% | 12 | Mar 16, 2026 | |
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.95 | -7.56% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $73.80 | +17.89% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $3.49 | -21.20% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $11.48 | +48.08% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $413.59 | +17.27% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $83.90 | +13.23% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $43.40 | +10.60% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $5.90 | +120.34% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $203 → $210 | $189.32 | +10.92% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $202.82 | -8.29% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $18.42 | +52.01% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.45 | +106.90% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $25.90 | -11.20% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $24.20 | +271.90% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $178.40 | +56.95% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $156.66 | +58.30% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $116.17 | +119.51% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $311.43 | -11.70% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $257.14 | +1.11% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.29 | +249.34% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.06 | +4,852.83% | 2 | Jan 5, 2022 |
McKesson
Apr 6, 2026
Maintains: Buy
Price Target: $1,040 → $1,000
Current: $822.63
Upside: +21.56%
Hims & Hers Health
Mar 16, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $26.33
Upside: -5.05%
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.95
Upside: -7.56%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $73.80
Upside: +17.89%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $3.49
Upside: -21.20%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $11.48
Upside: +48.08%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $413.59
Upside: +17.27%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $83.90
Upside: +13.23%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.40
Upside: +10.60%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $5.90
Upside: +120.34%
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $189.32
Upside: +10.92%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $202.82
Upside: -8.29%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $18.42
Upside: +52.01%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.45
Upside: +106.90%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $25.90
Upside: -11.20%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $24.20
Upside: +271.90%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $178.40
Upside: +56.95%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $156.66
Upside: +58.30%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $116.17
Upside: +119.51%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $311.43
Upside: -11.70%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $257.14
Upside: +1.11%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.29
Upside: +249.34%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.06
Upside: +4,852.83%